HCC202細胞
數量： 大量
運輸方式： 凍存運輸
組織來源： duct
年限： TNM stage IIIA, grade 3
是否是腫瘤細胞： 1
物種來源： 人
ATCC Number： CRL-2316?
相關**： 導管癌
生長狀態： 貼壁生長
器官來源： **
Designations: HCC202
Depositors: AF Gazdar, AK Virmani
HCC202細胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent, The line grows as attached medium-sized epithelial cells with some floating cells.
Organism: Homo sapiens
Morphology:
Source: Organ: mammary gland; breast
Tissue: duct
Tumor Stage: TNM stage IIIA, grade 3
Disease: primary ductal carcinoma
Cellular Products: Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. HCC202細胞They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
Applications: The cells are poorly differentiated.
The cells are positive for expression of Her2-neu, but are negative for expression of p53.
HCC202 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER -) and progesterone receptor (PR -).
Receptors: estrogen receptor, negative
progesterone receptor, negative
Oncogene: her2/neu +, p53 -
DNA Profile (STR): Amelogenin: X
CSF1PO: 10
D13S317: 8,9
D16S539: 13
D5S818: 11,13
D7S820: 8,12
THO1: 6
TPOX: 8,9
vWA: 16
Cytogenetic Analysis: polyploid
Age: 82 years
Gender: female
Ethnicity: HCC202細胞Caucasian, White
Comments: The HCC202 cell line was initiated from a primary ductal carcinoma on September 5, 1992, and took 41 months to establish.
The tumor was classified as TNM Stage IIIA, grade 3, invasive ductal carcinoma with metastases in 4 out of 19 lymph nodes.
The cells are poorly differentiated.
The cells are positive for expression of Her2-neu, but are negative for expression of p53.
HCC202 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER -) and progesterone receptor (PR -).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, rinse with 0.25% trypsin, 0.03% EDTA solution, add an additional 1 to 2 ml of trypsin solution and allow the flask to set at room temperature (or incubate at 37C) until cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products: HCC202細胞Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
